



IFU

Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 27th day of April 2007.

(s) Helen J. Glenister
Helen J. Glenister

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vitiello et al.

Atty. Docket: PRD2091US-PCT

US National Phase of: PCT/US2004/038648

Art Unit: unknown

International filing date: November 17, 2004

Examiner: unknown

National Stage Serial No.: 10/579,458

Confirmation No. 3414

For: Animal Models For The Systemic Inflammatory Response To Infection

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. § 1.56 and in accordance with 37 C.F.R. §§ 1.97-1.98, Applicant submits the accompanying Form PTO-1449 citing references relating to the application.

This Statement is being filed under the provisions of 37 C.F.R. § 1.97(b)(3), i.e., before the mailing of a first Office Action on the merits. In the event that a first Office Action on the merits has been mailed, then this Statement is being filed under 37 C.F.R. § 1.97(c)(2) and the Commissioner is requested to charge Deposit Account No. 10-0750 for the fee set forth in 37 C.F.R. § 1.17(p).

A copy of each reference listed on the Form PTO-1449 is enclosed. Each reference is in the English language. A copy of the International Search Report is also enclosed.


This Statement should not be construed as an admission that any information provided herewith is material as that term is defined in 37 C.F.R. § 1.56(b) or that any cited reference qualifies as prior art. This Statement should not be construed as a representation that a search has been made, or that information more material does not exist.

The Examiner is respectfully requested to initial the citations on the Form PTO-1449 to confirm consideration of each reference.

If any fees are due in connection with the filing of this Statement, please charge any necessary fees to Deposit Account No. 10-0750.

Respectfully submitted,

Date: April 27, 2007


Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

PRD2091US-PCT

10/579,458

**INFORMATION DISCLOSURE
CITATION BY APPLICANT**

(Use several sheets if necessary)

APPLICANT

Vitiello et al.

INT'L FILING DATE

November 17, 2004

GROUP ART UNIT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	INVENTORS	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 2004	0 2 0 9 9 2 9	Oct. 21, 2004	Skalitzky et al.			
	US 2004	0 1 9 8 7 1 9	Oct. 7, 2004	Laborde et al.			
	US 2004	0 1 8 6 1 6 6	Sept. 23, 2004	Burstein et al.			
	US 2004	0 1 8 6 1 4 3	Sept. 23, 2004	Carter et al.			
	US 2004	0 1 8 6 1 4 0	Sept. 23, 2004	Cherney et al.			
	US 2004	0 1 7 1 5 5 2	Sept. 2, 2004	Peled et al.			
	US 2004	0 1 6 2 3 5 4	Aug. 19, 2004	Evans et al.			
	US 2004	0 1 5 7 2 4 2	Aug. 12, 2004	Ivey et al.			
	US 2004	0 1 5 1 7 2 1	Aug. 5, 2004	O'Keefe et al.			
	US 2004	0 1 2 1 3 5 0	June 24, 2004	Anderberg et al.			
	US 2003	0 1 9 4 7 5 2	Oct. 16, 2003	Anderson et al.			
		6 6 7 0 3 6 4	Dec. 30, 2003	Laborde et al.			
		6 6 1 0 5 0 3	Aug. 26, 2003	Bellinger-Kawahara et al.			
		6 5 7 9 9 8 3	June 17, 2003	Batchelor et al.			
		6 3 6 8 5 7 2	April 9, 2002	Reisner et al.			
		6 1 9 0 8 7 2	Feb 20, 2001	Slotman			
		5 8 0 4 3 7 0	Sept. 8, 1998	Romaschin et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY/REGION	CLASS	SUBCLASS	TRANSLATION (if applicable)
	WO 200 6 0 8 5 9 6 1	Aug. 17, 2006	WIPO			
	WO 0 1 3 2 6 5 1	May 10, 2001	WIPO			
	WO 9 8 1 3 3 5 4	April 2, 1998	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Angus et al., <i>Crit. Care Med.</i> , 2001, Vol. 29(7), pages 1303-1310.
	Bone et al., <i>Chest</i> , 1992, Vol. 101(6), pages 1644-1654.
	Cleveland, <i>J. Amer. Statist. Assoc.</i> , 1979, Vol. 74(368), pages 829-836.
	Cohen, <i>Nature</i> , 2002, Vol. 420, pages 885-891.
	De St. Groth et al., <i>J. Immun. Methods</i> , 1980, Vol. 35, pages 1-21.
	Doughty et al., <i>Crit. Care Med.</i> , 1996, Vol. 24(7), pages 1137-1143.
	Espineda et al., <i>Cancer</i> , 2003, Vol. 97(8), pages 1859-1868.
	Fernandez et al., <i>Antimicrob. Agents Chemo.</i> , 1999, Vol. 43(3), pages 667-671.
	Ferreira et al., <i>JAMA</i> , 2001, Vol. 286(14), pages 1754-1758.
	Fuursted et al., <i>J. Antimicrob. Chemother.</i> , 2002, Vol. 50, pages 421-424.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PRD2091US-PCT	SERIAL NO. 10/579,458
INFORMATION DISCLOSURE CITATION BY APPLICANT (Use several sheets if necessary)		APPLICANT Vitiello et al.	
		INT'L FILING DATE November 17, 2004	GROUP ART UNIT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hotchkiss et al., <i>N. Engl. J. Med.</i> , 2003, Vol. 348(2), pages 138-150.
	Kim et al., <i>Clin. Cancer Res.</i> , 2004, Vol. 10, pages 5464-5471.
	Kim et al., <i>J. Urol.</i> , 2005, Vol. 173, pages 1496-1501.
	Kiriakidis et al., <i>J. Cell Sci.</i> , 2003, Vol. 116(4), pages 665-674.
	Lemaitre et al., <i>Cell</i> , 1996, Vol. 86, pages 973-983.
	Leteurtre et al., <i>Med. Decis. Making</i> , 1999, Vol. 19(4), pages 399-410.
	Levy et al., <i>Crit. Care Med.</i> , 2003, Vol. 31(4), pages 1250-1256.
	Marshall et al., <i>Crit. Care Med.</i> , 1995, Vol. 23(10), pages 1638-1652.
	Mischel et al., <i>Oncogene</i> , 2003, Vol. 22, pages 2361-2373.
	Motley et al., <i>Cell. Microbiol.</i> , 2004, Vol. 6(9), pages 849-865.
	Netea et al., <i>Trends. Immunol.</i> , 2003, Vol. 24(5), pages 254-258.
	Nika et al., <i>Infect. Immun.</i> , 2002, Vol. 70(6), pages 2965-2975.
	Proulx et al., <i>Chest</i> , 1996, Vol. 109(4), pages 1033-1037.
	Rangel-Frausto, <i>Infect. Dis. Clin. North Am.</i> , 1999, Vol. 13(2), pages 299-312.
	Rangel-Frausto et al., <i>JAMA</i> , 1995, Vol. 273(2), pages 117-123.
	Roumen et al., <i>J. Trauma</i> , 1993, Vol. 35(3), pages 349-355.
	Shai et al., <i>Oncogene</i> , 2003, Vol. 22, pages 4918-4923.
	Shi et al., <i>Mod. Pathol.</i> , 2005, Vol. 18, pages 547-557.
	Takala et al., <i>Clin. Sci.</i> , 1999, Vol. 96, pages 287-295.
	Ward et al., <i>Infect. Immun.</i> , 2003, Vol. 71(5), pages 2478-2486.
	Ward et al., <i>Infect. Immun.</i> , 2004, Vol. 72(4), pages 1874-1884.
	Wilkinson et al., <i>Crit. Care Med.</i> , 1986, Vol. 14(4), pages 271-274.
	Yagel et al., <i>Antimicrob. Agents Chemother.</i> , 1996, Vol. 40(12), pages 2894-2897.
	Yano et al., <i>J. Exp Med.</i> , 2006, Vol. 203(6), pages 1447-1458.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.